To Get Full Access :

Lumisight

Lumisight is an IV fluorescent imaging agent used during lumpectomy to highlight residual breast cancer tissue inside the surgical cavity. This real-time tool helps surgeons ensure more complete tumor removal and aims to lower the need for additional surgery.

The information outlined in the molecule details section below would help you evaluate Para IV filing opportunities early to secure a first-to-file advantage.

Molecule Details :

  • Molecule Name :

    Pegulicianine
  • Innovator :

    LUMICELL INC
  • Approval Date :

    17-Apr-24
  • NCE-1 Date :

    17-Apr-28
  • NCE Date :

    17-Apr-29
  • Dosage Form :

    Intravenous Powder Injection
  • Strength :

    EQ 40MG BASE/VIAL
  • Therapeutic Category :

    Diagnostic Agents
  • Revenue ($M) :

    NA

Year-wise Projected Sales ($M) :

  • 2025 :

    NA
  • 2026 :

    NA
  • 2027 :

    NA
  • 2028 :

    NA
  • 2029 :

    NA
  • 2030 :

    NA
  • 2031 :

    NA
Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.

Why Partner With Us

Login With

For full access Sign-up / Sign-in using below Methods:

By continuing, you agree to our Terms & Conditions and Privacy Policy. You can review them anytime.

Are you sure want to logout from NCE Grid?